decisionhealth Newsletters, Part B News - 2004 Issue 8 (August)
MMA pay cut for drugs that treat prostate cancer shouldn't determine what you prescribe
Subscribe or sign in to view the full article.
Article Overview
This article discusses how Medicare payment changes for prostate cancer drug treatments were affecting practice behavior at the end of 2004 and into 2005. It is aimed at physicians, practice managers, and coding/billing professionals who need to understand the general compliance and documentation issues raised by the transition in reimbursement methodology. The piece also references Medicare medical necessity standards and the role of carrier review in assessing whether treatment changes are supported by the medical record.
Why This Topic Matters
It highlights a reimbursement transition that could influence prescribing and billing decisions for long-duration drug therapy, especially when treatment spans calendar years. The article is relevant to practices that want to reduce compliance risk and document medical necessity appropriately.
What You Will Learn
- How Medicare payment policy changes can affect drug therapy billing across year-end transitions.
- Why medical necessity documentation matters when treatment regimens are changed.
- What kinds of compliance concerns carriers may review in relation to prostate cancer drug therapy.
- How reimbursement methodology changes can affect practice financial incentives.
Who Should Read This
- Physicians
- Oncology practices
- Urology practices
- Medical coders
- Medical billers
- Practice managers
- Compliance staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com